Your browser doesn't support javascript.
loading
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce, Filipa; Mainor, Candace; Donahue, Renee N; Geng, Xue; Jones, Greg; Schlam, Ilana; Wang, Hongkun; Toney, Nicole J; Jochems, Caroline; Schlom, Jeffrey; Zeck, Jay; Gallagher, Christopher; Nanda, Rita; Graham, Deena; Stringer-Reasor, Erica M; Denduluri, Neelima; Collins, Julie; Chitalia, Ami; Tiwari, Shruti; Nunes, Raquel; Kaltman, Rebecca; Khoury, Katia; Gatti-Mays, Margaret; Tarantino, Paolo; Tolaney, Sara M; Swain, Sandra M; Pohlmann, Paula; Parsons, Heather A; Isaacs, Claudine.
Affiliation
  • Lynce F; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.
  • Mainor C; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.
  • Donahue RN; Harvard Medical School, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.
  • Geng X; MedStar Georgetown University Hospital, Washington, DC, USA.
  • Jones G; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Schlam I; Georgetown University, Washington, DC, USA.
  • Wang H; NeoGenomics, Durham, NC, USA.
  • Toney NJ; MedStar Washington Hospital Center, Washington, DC, USA.
  • Jochems C; Tufts Medical Center, Boston, MA, USA.
  • Schlom J; Georgetown University, Washington, DC, USA.
  • Zeck J; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Gallagher C; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Nanda R; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Graham D; MedStar Georgetown University Hospital, Washington, DC, USA.
  • Stringer-Reasor EM; MedStar Washington Hospital Center, Washington, DC, USA.
  • Denduluri N; University of Chicago, Chicago, IL, USA.
  • Collins J; Hackensack University Medical Center, Hackensack, NJ, USA.
  • Chitalia A; University of Alabama at Birmingham, Birmingham, AL, USA.
  • Tiwari S; AstraZeneca, Arlington, VA, USA.
  • Nunes R; MedStar Georgetown University Hospital, Washington, DC, USA.
  • Kaltman R; AstraZeneca, Arlington, VA, USA.
  • Khoury K; MedStar Washington Hospital Center, Washington, DC, USA.
  • Gatti-Mays M; MedStar Washington Hospital Center, Washington, DC, USA.
  • Tarantino P; Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA.
  • Tolaney SM; AstraZeneca, Arlington, VA, USA.
  • Swain SM; Inova, Fairfax, VA, USA.
  • Pohlmann P; University of Alabama at Birmingham, Birmingham, AL, USA.
  • Parsons HA; The Ohio State University, Columbus, OH, USA.
  • Isaacs C; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nat Commun ; 15(1): 3957, 2024 May 10.
Article in En | MEDLINE | ID: mdl-38730268
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2024 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2024 Document type: Article Affiliation country: United States